# US 2025/0206751 A1 · Heterocyclic compound for inducing degradation of g12d mutant kras protein

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0206751 A1
- Document ID: US20250206751A1
- Status: Published application
- Kind: A1
- Application number: 18/845,652
- Filed: 2023-03-10
- Published: 2025-06-26
- Earliest claimed: 2022-03-11
- Assignees: Astellas Pharma Inc.
- Applicants: Astellas Pharma Inc.
- Inventors: Tomohiro YOSHINARI; Kenichi KAWAGUCHI; Eiji KAWAMINAMI; Hiroki ISHIOKA; Hideyuki WATANABE; Tomoyoshi IMAIZUMI; Hisao HAMAGUCHI; Fumie TAKAHASHI; Takahiro MORIKAWA; Kazuyuki KURAMOTO; Takeyuki NAGASHIMA; Kohei INAMURA
- Web page: https://patentgrep.com/patent/US20250206751A1

## CPC

- C07D 487/08: Bridged systems
- A61K 31/4709: Non-condensed quinolines and containing further heterocyclic rings
- A61K 31/4995: Pyrazines or piperazines forming part of bridged ring systems
- A61K 31/517: ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 35/00: Antineoplastic agents
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 401/14: containing three or more hetero rings
- C07D 403/14: containing three or more hetero rings
- C07D 405/14: containing three or more hetero rings
- C07D 407/14: containing three or more hetero rings
- C07D 413/14: containing three or more hetero rings
- C07D 417/14: containing three or more hetero rings
- C07D 471/04: Ortho-condensed systems
- C07D 487/04: Ortho-condensed systems
- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

To provide a compound useful as an active ingredient of a pharmaceutical composition for treating pancreatic cancer. The present inventors have studied about a compound that is useful as an active ingredient of a pharmaceutical composition for treating pancreatic cancer and have found that heterocyclic compounds represented by the formula (I) and the formula (IA) have an excellent degradation-inducing action on a G12D mutant KRAS protein and a G12D mutant KRAS inhibition activity and can be used as a therapeutic agent for pancreatic cancer, thus completing the present invention. The heterocyclic compound or a salt thereof of the present invention can be used as a therapeutic agent for pancreatic cancer.

## Claims

### Claim 1

A compound of the formula (IA) or a salt thereof,
wherein in the formula,
A is CRA or N,
RA is H or C1-3 alkyl,
E is CH or N,
G is CR2 or N, and
R1 is naphthyl optionally substituted with OH or a group selected from the group consisting of the formula (II), the formula (III) and the formula (IV) below,
wherein,
R1a and R1b, which are the same as or different from each other, are H, methyl, F or Cl,
R1c is F, Cl, methyl or ethyl,
R2 is H, halogen, optionally substituted C1-3 alkyl, cyclopropyl or vinyl,
R3 is —P-Q or V,
P is —CH2—, —O— or —N(RP)—,
RP is H or optionally substituted C1-3 alkyl, and
Q is the formula (V) or the formula (VI) below,
V is the formula (VII) below,
each RQ, which is the same as or different from each other, is OH or C1-3 alkyl, wherein RQ is attached only to a carbon atom that is an atom forming a ring selected from the group consisting of an azetidine ring represented by the formula (V), a pyrrolidine ring represented by the formula (VI), and a piperazine ring represented by the formula (VII),
(i) when A is CRA or (ii) when A is N, and E or G is N,
V may be a 7-membered or 8-membered saturated or unsaturated bridged heterocyclic group in addition to the formula (VII),
m is 0 to 2,
R4 is optionally substituted C1-6 alkyl, a 4-membered to 6-membered optionally substituted saturated heterocyclic group containing one or two hetero atoms selected from the group consisting of oxygen, sulfur and nitrogen, 5-membered optionally substituted heteroaryl containing one to four hetero atoms selected from the group consisting of oxygen, sulfur and nitrogen, or 6-membered optionally substituted heteroaryl containing one to three nitrogen atoms,
R5 is optionally substituted C1-6 alkyl, optionally substituted C3-6 cycloalkyl, or a 4-membered to 6-membered optionally substituted saturated heterocyclic group containing one hetero atom selected from the group consisting of oxygen, sulfur and nitrogen,
R6a and R6b, which are the same as or different from each other, are H or optionally substituted C1-6 alkyl, or R6a and R6b may form together with the carbon to which they are attached, optionally substituted C3-6 cycloalkyl or a 4-membered to 6-membered optionally substituted saturated heterocyclic group containing one hetero atom selected from the group consisting of oxygen, sulfur, and nitrogen,
R7 is H, halogen, C1-3 alkyl, —SO2CH3, C3-6 cycloalkyl, a 4-membered to 6-membered optionally substituted saturated heterocyclic group containing one or two hetero atoms selected from the group consisting of oxygen, sulfur, and nitrogen, 5-membered optionally substituted heteroaryl containing one to four hetero atoms selected from the group consisting of oxygen, sulfur, and nitrogen, or 6-membered heteroaryl containing one to three nitrogen atoms,
LY is —O-(optionally substituted C1-3 alkylene)-, —S-(optionally substituted C1-3 alkylene)-, —SO2-(optionally substituted C1-3 alkylene)-, —NRY-(optionally substituted C1-3 alkylene)-, -(optionally substituted C1-3 alkylene)-O—, -(optionally substituted C1-3 alkylene)-S—, -(optionally substituted C1-3 alkylene)-SO2—, or -(optionally substituted C1-3 alkylene)-NRY—,
RY is H or C1-3 alkyl,
RP1 is OH or F,
RP2a is H or F,
RP2b is H,
W is optionally substituted phenylene or 6-membered optionally substituted heteroarenediyl containing one to three nitrogen atoms,
X is a bond, —CH2—, —O—, —S—, or —NR4x—,
R4x is H or C1-3 alkyl,
Y is phenylene or pyridinediyl, wherein the phenylene may be substituted with F,
L is -(L1-L2-L3-L4)-,
L1, L2, L3 and L4, which are the same as or different from each other, are a group selected from the group consisting of a bond, —O—, —NRL1—, optionally substituted pyrrolidinediyl, optionally substituted piperidinediyl, optionally substituted piperazinediyl, optionally substituted C1-3 alkylene, and C═O,
RL1 is H or C1-3 alkyl, and
Z is NH or 5-membered heteroarenediyl containing one to four hetero atoms selected from the group consisting of oxygen, sulfur and nitrogen,
or Y-L-Z is the formula (VIII) below:

### Claim 2

A compound of the formula (I) or a salt thereof,
wherein in the formula,
A is CRA or N,
RA is H or C1-3 alkyl, and
R1 is naphthyl optionally substituted with OH or a group selected from the group consisting of the formula (II), the formula (III), and the formula (IV) below,
R1a and R1b, which are the same as or different from each other, are H, methyl, F, or Cl,
R1c is F, Cl, methyl, or ethyl,
R2 is H, halogen, optionally substituted C1-3 alkyl, cyclopropyl, or vinyl,
R3 is —P-Q or V,
P is —CH2—, —O—, or —N(RP)—,
RP is H or optionally substituted C1-3 alkyl, and
Q is the formula (V) or the formula (VI) below,
V is the formula (VII) below,
each RQ, which is the same as or different from each other, is OH or C1-3 alkyl, wherein RQ is attached only to a carbon atom that is an atom forming a ring selected from the group consisting of an azetidine ring represented by the formula (V), a pyrrolidine ring represented by the formula (VI), and a piperazine ring represented by the formula (VII),
m is 0 to 2,
R4 is optionally substituted C1-6 alkyl, a 4-membered to 6-membered optionally substituted saturated heterocyclic group containing one or two hetero atoms selected from the group consisting of oxygen, sulfur, and nitrogen, 5-membered optionally substituted heteroaryl containing one to four hetero atoms selected from the group consisting of oxygen, sulfur, and nitrogen, or 6-membered optionally substituted heteroaryl containing one to three nitrogen atoms,
R5 is optionally substituted C1-6 alkyl, optionally substituted C3-6 cycloalkyl or a 4-membered to 6-membered optionally substituted saturated heterocyclic group containing one hetero atom selected from the group consisting of oxygen, sulfur, and nitrogen,
R6a and R6b, which are the same as or different from each other, are H or optionally substituted C1-6 alkyl, or R6a and R6b may form together with the carbon to which they are attached, optionally substituted C3-6 cycloalkyl or a 4-membered to 6-membered optionally substituted saturated heterocyclic group containing one hetero atom selected from the group consisting of oxygen, sulfur, and nitrogen,
R7 is H, halogen, C1-3 alkyl, —SO2CH3, C3-6 cycloalkyl, a 4-membered to 6-membered optionally substituted saturated heterocyclic group containing one or two hetero atoms selected from the group consisting of oxygen, sulfur, and nitrogen, 5-membered optionally substituted heteroaryl containing one to four hetero atoms selected from the group consisting of oxygen, sulfur, and nitrogen, or 6-membered heteroaryl containing one to three nitrogen atoms,
W is optionally substituted phenylene or 6-membered optionally substituted heteroarenediyl containing one to three nitrogen atoms,
X is a bond, —CH2—, —O—, —S— or —NR4x—,
R4x is H or C1-3 alkyl,
Y is phenylene or pyridinediyl, wherein the phenylene may be substituted with F,
L is -(L1-L2-L3-L4)-,
L1, L2, L3 and L4, which are the same as or different from each other, are a group selected from the group consisting of a bond, —O—, —NRL1—, optionally substituted pyrrolidinediyl, optionally substituted piperidinediyl, optionally substituted piperazinediyl, optionally substituted C1-3 alkylene, and C═O,
RL1 is H or C1-3 alkyl, and
Z is NH or 5-membered heteroarenediyl containing one to four hetero atoms selected from the group consisting of oxygen, sulfur, and nitrogen,
or Y-L-Z is the formula (VIII) below;

### Claim 3 (depends on 2)

The compound or a salt thereof according to claim 2, wherein
Y is phenylene or pyridinediyl, wherein the phenylene may be substituted with F,
L is a bond, C1-3 alkylene, C═O or a group selected from the group consisting of the formula (XX), the formula (XXI), the formula (XXII), the formula (XXIII), the formula (XXIV), and the formula (XXV) below,
RL1 is H or C1-3 alkyl,
RL2 and RL3, which are the same as or different from each other, are H, F, OH, OCH3, or optionally substituted C1-3 alkyl,
RL is CH or N,
n is an integer of one or two, and
Z is NH or a group selected from the group consisting of the formula (XXVI), the formula (XXVII), the formula (XXVIII), and the formula (XXIX) below,
or Y-L-Z is the formula (VIII) below:

### Claim 4 (depends on 3)

The compound or a salt thereof according to claim 3, wherein R1 is the formula (IIa) or the formula (IIIa) below,
R1a and R1b, which are the same as or different from each other, are H, methyl, F, or Cl,
R3 is as follows,
(i) when A is CRA, R3 is —P-Q, and
P is —O—, or
(ii) when A is N, R3 is —P-Q or V, P is —O— or —N(RP)—, and
RP is H or C1-3 alkyl,
in either case (i) or (ii), Q is the formula (V) or the formula (VI) below,
V is the formula (VII) below,
each RQ, which is the same as or different from each other, is OH or methyl, wherein RQ′ is attached only to a carbon atom that is an atom forming a ring selected from the group consisting of an azetidine ring represented by the formula (V), a pyrrolidine ring represented by the formula (VI), and a piperazine ring represented by the formula (VII), and
m is 0 to 2,
R4 is optionally substituted C1-6 alkyl, a 4-membered to 6-membered optionally substituted saturated heterocyclic group containing one or two hetero atoms selected from the group consisting of oxygen, sulfur, and nitrogen, optionally substituted pyrazolyl, optionally substituted pyridyl, or optionally substituted pyrimidinyl,
R5 is methyl, ethyl, isopropyl, tert-butyl, or C3-6 cycloalkyl,
R6a and R6b, which are the same as or different from each other, are H or C1-3 alkyl, wherein the C1-3 alkyl may be substituted with a group selected from the group consisting of F, OH, OCH3, and N(CH3)2, or R6a and R6b may form C3-6 cycloalkyl together with the carbon to which they are attached,
R7 is H, halogen, C1-3 alkyl, —SO2CH3, C3-6 cycloalkyl, or a group selected from the group consisting of the formula (IX), the formula (X), the formula (XI), the formula (XII), the formula (XIII), the formula (XIV), the formula (XV), the formula (XVI), the formula (XVII), and the formula (XVIII) below,
R7a and R7b, which are the same as or different from each other, are H or C1-3 alkyl optionally substituted with OH, and
W is the following formula (XIX),
W1 and W2 are as follows,
(i) W1 is CH, and W2 is C—SO2CH3, or
(ii) W1 and W2, which are the same as or different from each other, are CH, CF, CCl, CCH3, or N,
wherein when W1 is CH and W2 is C—SO2CH3, R7 is H,
X is —O or —NR4x—,
R4x is H or C1-3 alkyl,
Y is phenylene or pyridinediyl, wherein the phenylene may be substituted with F,
L is a bond, C═O, or a group selected from the group consisting of the formula (XX) and the formula (XXII) below,
RL1 is H or C1-3 alkyl,
RL2 and RL3, which are the same as or different from each other, are H, F, OH, OCH3, or optionally substituted C1-3 alkyl,
n is an integer of one or two, and
Z is NH or a group selected from the group consisting of the formula (XXVI), the formula (XXVII), the formula (XXVIII), and the formula (XXIX) below,
or Y-L-Z is the formula (VIII) below,

### Claim 5 (depends on 4)

The compound or a salt thereof according to claim 4,
wherein A is CH or N,
R2 is halogen, C1-3 alkyl, cyclopropyl, or vinyl, wherein the C1-3 alkyl may be substituted with a group selected from the group consisting of OH and OCH3,
R3 is as follows,
(i) when A is CH, R3 is —P-Q, and
P is —O—, or
(ii) when A is N, R3 is —P-Q or V,
P is —O— or —N(RP)—,
RP is H or C1-3 alkyl,
in either case (i) or (ii), Q is the formula (V) or the formula (VI) below,
V is the formula (VII) below,
each RQ, which is the same as or different from each other, is OH or methyl, wherein RQ is attached only to a carbon atom that is an atom forming a ring selected from the group consisting of an azetidine ring represented by the formula (V), a pyrrolidine ring represented by the formula (VI), and a piperazine ring represented by the formula (VII), and
m is 0 to 2,
R4 is C1-6 alkyl optionally substituted with a group selected from the group consisting of F, OH, OCH3, CF3, CHF2, optionally substituted cyclopropyl, optionally substituted pyrrolidinyl, and optionally substituted tetrahydrofuranyl or tetrahydropyranyl, and
R7 is halogen or a group selected from the group consisting of the formula (IX), the formula (X), the formula (XI), the formula (XII), the formula (XIII), and the formula (XIV) below,
R7a and R7b, which are the same as or different from each other, are H or C1-3 alkyl optionally substituted with OH,
W is the following formula (XIX),
W1 and W2, which are the same as or different from each other, are CH or N,
X is —O— or —NH—,
Y is phenylene or pyridinediyl, wherein the phenylene may be substituted with F,
L is a bond, and
Z is the formula (XXVII) below,

### Claim 6 (depends on 4)

The compound or a salt thereof according to claim 4,
wherein A is N,
R3 is —P-Q,
P is —O— or —N(RP)—,
RP is H or C1-3 alkyl, and
Q is the formula (V) or the formula (VI) below,
each RQ, which is the same as or different from each other, is OH or methyl, wherein RQ is attached only to a carbon atom that is an atom forming a ring selected from the group consisting of an azetidine ring represented by the formula (V) and a pyrrolidine ring represented by the formula (VI),
m is 0 to 2, and
W is the following formula (XIX),
W1 and W2, which are the same as or different from each other, are CH, CF, CCl, CCH3, or N,
Y is phenylene or pyridinediyl, wherein the phenylene may be substituted with F,
L is a bond, C═O or a group selected from the group consisting of the formula (XX) and the formula (XXII) below,
RL1 is H or C1-3 alkyl,
RL2 and RL3, which are the same as or different from each other, are H, F, OH, OCH3, or optionally substituted C1-3 alkyl,
n is an integer of one or two, and
Z is NH or a group selected from the group consisting of the formula (XXVI), the formula (XXVII), the formula (XXVIII), and the formula (XXIX) below,

### Claim 7 (depends on 4)

The compound or a salt thereof according to claim 4,
wherein A is CH,
R3 is —P-Q,
P is —O—, and
Q is the formula (V) or the formula (VI) below,
each RQ, which is the same as or different from each other, is OH or methyl, wherein RQ is attached only to a carbon atom that is an atom forming a ring selected from the group consisting of an azetidine ring represented by the formula (V) and a pyrrolidine ring represented by the formula (VI),
m is 0 to 2, and
W is the following formula (XIX),
W1 and W2, which are the same as or different from each other, are CH, CF, CCl, CCH3, or N,
Y is phenylene or pyridinediyl, wherein the phenylene may be substituted with F, and
L is a bond, C═O, or a group selected from the group consisting of the formula (XX) and the formula (XXII) below,
RL1 is H or C1-3 alkyl,
RL2 and RL3, which are the same as or different from each other, are H, F, OH, OCH3, or optionally substituted C1-3 alkyl,
n is an integer of one or two, and
Z is NH or a group selected from the group consisting of the formula (XXVI), the formula (XXVII), the formula (XXVIII), and the formula (XXIX) below,

### Claim 8 (depends on 4)

The compound or a salt thereof according to claim 4,
wherein A is N,
R3 is V, and
V is the formula (VII) below,
each RQ, which is the same as or different from each other, is OH or methyl, wherein RQ is attached only to a carbon atom that is a ring-forming atom of a piperazine ring represented by the formula (VII),
m is 0 to 2, and
W is the following formula (XIX),
W1 and W2, which are the same as or different from each other, are CH, CF, CCl, CCH3, or N,
Y is phenylene or pyridinediyl, wherein the phenylene may be substituted with F, and
L is a bond, C═O, or a group selected from the group consisting of the formula (XX) and the formula (XXII) below,
RL1 is H or C1-3 alkyl,
RLa and RL3, which are the same as or different from each other, are H, F, OH, OCH3, or optionally substituted C1-3 alkyl,
n is an integer of one or two, and
Z is NH or a group selected from the group consisting of the formula (XXVI), the formula (XXVII), the formula (XXVIII), and the formula (XXIX) below,

### Claim 9 (depends on 5)

The compound or a salt thereof according to claim 5,
wherein A is N, and
R1 is the formula (IIb) below,
R3 is —P-Q,
P is —O— or —N(RP)—,
RP is H or C1-3 alkyl, and
Q is the formula (V) or the formula (VI) below,
each RQ, which is the same as or different from each other, is OH or methyl, wherein RQ is attached only to a carbon atom that is an atom forming a ring selected from the group consisting of an azetidine ring represented by the formula (V) and a pyrrolidine ring represented by the formula (VI),
m is 0 or 1, and
X is —O—.

### Claim 10 (depends on 9)

The compound or a salt thereof according to claim 9,
wherein R2 is cyclopropyl,
R3 is —P-Q,
P is —N(RP)—,
RP is H or C1-3 alkyl, and
Q is the formula (V) or the formula (VI) below,
each RQ, which is the same as or different from each other, is OH or methyl, wherein RQ is attached only to a carbon atom that is an atom forming a ring selected from the group consisting of an azetidine ring represented by the formula (V) and a pyrrolidine ring represented by the formula (VI),
m is 0 or 1,
R4 is C1-6 alkyl optionally substituted with a group selected from the group consisting of OCH3 and a tetrahydrofuranyl group or tetrahydropyranyl,
R5 is isopropyl,
R6a is H, and R6b is C1-3 alkyl optionally substituted with OH, and
R7 is the formula (IX), the formula (X), the formula (XI), or the formula (XII) below,
R7a is C1-3 alkyl optionally substituted with OH, and
W is the following formula (XIX),
W1 and W2 are each CH, and
Y is phenylene optionally substituted with F.

### Claim 11 (depends on 1, 2)

The compound or a salt thereof according to any of claims 1 or 2,
wherein compounds of the formula (I) and the formula (IA) are selected from the group consisting of
(4R)-1-[(2S)-2-{4-[4-({[(7M)-6-cyclopropyl-7-(6-fluoro-5-methyl-1H-indazol-4-yl)-4-{methyl[(3S)-pyrrolidin-3-yl]amino}-2-{[(2R)-oxolan-2-yl]methoxy}quinazolin-8-yl}oxy}methyl)phenyl]-1H-1,2,3-triazol-1-yl}-3-methylbutanoyl]-4-hydroxy-N-{(1R)-2-hydroxy-1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]ethyl}-L-prolinamide,
(4R)-1-[(2S)-2-{4-[4-({[(7M)-6-cyclopropyl-7-(6-fluoro-5-methyl-1H-indazol-4-yl)-4-{methyl[(3S)-pyrrolidin-3-yl]amino}-2-{[(2S)-oxolan-2-yl]methoxy}quinazolin-8-yl}oxy}methyl)phenyl]-1H-1,2,3-triazol-1-yl}-3-methylbutanoyl]-4-hydroxy-N-{(1R)-2-hydroxy-1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]ethyl}-L-prolinamide,
(4R)-1-[(2S)-2-{4-[4-({[(7M)-6-cyclopropyl-7-(6-fluoro-5-methyl-1H-indazol-4-yl)-2-[(2S)-2-methoxypropoxy]-4-{methyl[(3S)-pyrrolidin-3-yl]amino}quinazolin-8-yl]oxy}methyl)phenyl]-1H-1,2,3-triazol-1-yl}-3-methylbutanoyl]-4-hydroxy-N-{(1R)-2-hydroxy-1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]ethyl}-L-prolinamide,
(4R)-1-[(2S)-2-{4-[4-({[(7M)-6-cyclopropyl-7-(6-fluoro-5-methyl-1H-indazol-4-yl)-2-[(2S)-2-methoxypropoxy]-4-{methyl[(3S)-pyrrolidin-3-yl]amino}quinazolin-8-yl]oxy}methyl)phenyl]-1H-1,2,3-triazol-1-yl}-3-methylbutanoyl]-N-{(1R)-1-[4-(1-ethyl-1H-pyrazol-5-yl)phenyl]-2-hydroxyethyl}-4-hydroxy-L-prolinamide,
(4R)-1-[(2S)-2-{4-[4-({[(7M)-6-cyclopropyl-7-(6-fluoro-5-methyl-1H-indazol-4-yl)-2-[(2S)-2-methoxypropoxy]-4-{methyl[(3S)-pyrrolidin-3-yl]amino}quinazolin-8-yl]oxy}methyl}methyl)-2-fluorophenyl]-1H-1,2,3-triazol-1-yl}-3-methylbutanoyl]-4-hydroxy-N-{(1R)-2-hydroxy-1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]ethyl}-L-prolinamide,
(4R)-1-[(2S)-2-(4-{4-[({(7M)-6-cyclopropyl-4-{ethyl[(3S)-pyrrolidin-3-yl]amino}-7-(6-fluoro-5-methyl-1H-indazol-4-yl)-2-[(2S)-2-methoxypropoxy]quinazolin-8-yl}oxy)methyl)phenyl}-1H-1,2,3-triazol-1-yl)-3-methylbutanoyl]-4-hydroxy-N-{(1R)-2-hydroxy-1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]ethyl}-L-prolinamide, and
(4R)-1-[(2S)-2-{4-[4-({[(7M)-6-cyclopropyl-7-(6-fluoro-5-methyl-1H-indazol-4-yl)-2-[(2S)-2-methoxypropoxy]-4-{methyl[(3R)-pyrrolidin-3-yl]amino}quinazolin-8-yl]oxy}methyl)phenyl]-1H-1,2,3-triazol-1-yl}-3-methylbutanoyl]-4-hydroxy-N-{(1R)-2-hydroxy-1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]ethyl}-L-prolinamide.

### Claim 12 (depends on 1)

A pharmaceutical composition comprising the compound or a salt thereof according to claim 1 and one or more pharmaceutically acceptable excipients.

### Claim at position 13

13-16. (canceled)

### Claim 17 (depends on 1)

A method of treating pancreatic cancer, the method comprising administering an effective amount of the compound or a salt thereof according to claim 1 to a subject.

### Claim 18 (depends on 12)

A method of treating pancreatic cancer, the method comprising administering an effective amount of the pharmaceutical composition according to claim 12 to a subject.

### Claim 19 (depends on 2)

A method of treating pancreatic cancer, the method comprising administering an effective amount of the compound or a salt thereof according to claim 2 to a subject.

### Claim 20 (depends on 2)

A pharmaceutical composition comprising the compound or a salt thereof according to claim 2 and one or more pharmaceutically acceptable excipients.

### Claim 21 (depends on 20)

A method of treating pancreatic cancer, the method comprising administering an effective amount of the pharmaceutical composition according to claim 20 to a subject.
